Company profile
ContraFect Corp.
OTC: CFRXQ · Healthcare · Biotechnology
#1161 of 1,418 Healthcare companies by revenue
EA Score
——FH —DQ —GM —SS 32
v0.1 · 5/100 weight · pillars only
↑ listing tenure, disclosure history · ↓ Piotroski F, market scale
Methodology →Revenue TTM
$0
Rev growth YoY (TTM)
needs 8 qtrs
Net income (FY)
-$65.2M
Employees
23
as of 2026-08-31
Market cap
$107
as of 2026-08-31
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$0$02022
Net income-$65.2M-$65.2M2022
Operating income-$56.9M-$56.9M2022
Total assets$20.7M$20.7M2022
Liabilities$32.5M$32.5M2022
Equity-$11.9M-$11.9M2022
Revenue trend
FY2016 – FY2022 · USD
FY16
FY17
FY18
FY19
FY20
FY21
FY22
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is ContraFect Corp.’s revenue?
ContraFect Corp. booked $0 in FY2022 revenue — among the slowest-growing Healthcare companies we track, at a -Infinity% net margin.
Peers · Healthcare
Greenwind Holdings Inc.——Poniard Pharmaceuticals, Inc.——NexImmune, Inc.——Heart Tronics, Inc.——Nuvalent, Inc.——Apogee Therapeutics, Inc.——Neighbors
Westchester →Key facts
CEORoger J. Pomerantz
SectorHealthcare
IndustryBiotechnology
HeadquartersYonkers, NY
ExchangeOTC: CFRXQ
Employees23
IPO date2014-09-12
Latest filings
No filings loaded — no CIK (non-SEC filer).
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.